Susquehanna International Group
PSTV

Susquehanna International Group’s Plus Therapeutics PSTV Stock Holding History

Susquehanna International Group’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Hold
0
– -$16K – 9740
2016
Q4 		– Hold
0
– – – 9446
2014
Q4 		– Hold
0
– -$12K – 9992
2014
Q3 		– Hold
0
– – – 9343
2014
Q2 		– Hold
0
– – – 9001
2014
Q1 		– Hold
0
– – – 8447
2013
Q4 		– Hold
0
– – – 8537
2013
Q3 		– Hold
0
– – – 7609
2013
Q2 		– Hold
0
– – – 6301

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $149M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group's PSTV Position: Q4 2025 in Review

Susquehanna International Group sold out of Plus Therapeutics (PSTV) in Q4 2025, closing a stake of 2,691 shares — an estimated $46K sold.

Susquehanna International Group first reported a position in PSTV in Q2 2015 and held it in 8 quarters. The position peaked at $3.79M in Q2 2015. 25 funds tracked by Wall St. Rank hold PSTV as of Q4 2025.

  • Susquehanna International Group reported no remaining Plus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 2,691 Plus Therapeutics shares in Q4 2025, an estimated $46K.
  • Susquehanna International Group first reported a position in Plus Therapeutics in Q2 2015 and held it in 8 quarters.
  • Susquehanna International Group's Plus Therapeutics position peaked at $3.79M in Q2 2015.
  • 25 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.